WithdrawnPhase 1
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Reason given: IRB did not approve
Key facts
- Phase
- Phase 1
Trial details
- Who runs it
- Methodist Health System
- Trial code
- NCT06222437
- Record updated
- 23 March 2026
- Original description
The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.Read full original descriptionShow less
The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.
Inclusion: Age 18-45; Body mass index(BMI) > 30; Diagnosis of PCOS; Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone.
Exclusion: Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device; Letrozole, clomiphene citrate, FSH therapy; 5α reductase inhibitors; Androgen receptor blockers; Insulin; Hysterectomy; Endometrial ablation.